Abstract:Background: Anti-tumor necrosis factor (TNF) therapy appears to be effective in the treatment of Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract. However, the mechanisms involved are not completely understood. Methods: Fifty-seven active CD patients were enrolled, and cytokine profiles in colonic biopsies of patients with active CD receiving anti-TNF monoclonal antibody (mAb) (infliximab [IFX]) treatment were determined using quantitative real-time polymerase chain reaction (qRT-PCR). Colonic biopsies of active CD patients and healthy donors were cultured with IFX in vitro, and cytokine profiles were measured by qRT-PCR. Peripheral blood (PB)-CD4+ T cells were stimulated with anti-CD3 and anti-CD28 mAbs in the presence of human immunoglobin (HIg), IFX, recombinant human TNF-α converting enzyme (rhTACE), and aryl hydrocarbon receptor (AhR) inhibitor (CH-223191), respectively, to determine interleukin (IL)-22 expression by CD4+ T cells. Caco2 cells were also utilized to study their potential role in modulating epithelial cell barrier repairs in vitro. Results: IFX therapy markedly upregulated IL-22 mRNA expression in the gut mucosa of CD patients. In vitro treatment with IFX greatly promoted CD CD4+ T cells to express IL-22, which was inhibited by rhTACE, indicating that reverse signaling through binding to membrane-bound TNF mediates anti-TNF-induced IL-22 expression of CD CD4+ T cells. However, blockade of AhR markedly inhibited anti-TNF-induced IL-22+CD4+ T (Th22) cell differentiation in CD patients. Moreover, treatment with IL-22 induced intestinal epithelial cell expression of tight junction proteins (eg, claudin1 and ZO-1) and facilitated transepithelial resistance, indicating that IL-22 protects intestinal mucosa from inflammation via maintenance of epithelial barrier integrity. Conclusions: Our results uncover a novel mechanism whereby anti-TNF therapy upregulates IL-22 production in CD patients through promoting Th22 cell differentiation and contributes to intestinal epithelial barrier repairs.

Anti-TNF- α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease.

Blockage of Tumor Necrosis Factor Prevents Intestinal Mucosal Inflammation Through Down-Regulation of Interleukin-23 Secretion

Relationship between anti-tumor necrosis factor -α monoclonal antibody and chronic colitis in mice.

Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia Through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease

Tenascin-C is Increased in Inflammatory Bowel Disease and is Associated with Response to Infliximab Therapy

Monocyte Chemotactic Protein 1-Induced Protein 1 is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities

Tumor Necrosis Factor Suppresses Interleukin 10 in Peripheral B Cells Via Upregulating Bcl2-like Protein 12 in Patients with Inflammatory Bowel Disease.

Effect of Anti-Tnf-α Antibody on Mucosal Lymphocyte Apoptosis in Chronic Colitis Mice

Immune Regulatory Mechanisms of CD177+ Neutrophils in the Pathogenesis of Inflammatory Bowel Disease

Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response

Tumour Necrosis Factor Alpha (tnfα) Vaccines in the Downregulation of Bowel Inflammatory Responses in Mice

Anti-tumour Necrosis Factor Therapy Enhances Mucosal Healing Through Down-Regulation of Interleukin-21 Expression and T Helper Type 17 Cell Infiltration in Crohn's Disease

Mir-10A Inhibits Dendritic Cell Activation and Th1/Th17 Cell Immune Responses in IBD.

Blocking Tnf-Alpha By Combination Of Tnf-Alpha- And Tnfr-Binding Cyclic Peptide Ameliorates The Severity Of Tnbs-Induced Colitis In Rats

CD177 neutrophils as functionally activated neutrophils negatively regulate IBD.

Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease

Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease

Blockade of Complement Activation Product C5a Activity Using Specific Antibody Attenuates Intestinal Damage in Trinitrobenzene Sulfonic Acid Induced Model of Colitis

Determination of serum TNF-α and IL-8 in patients with inflammatory bowel disease

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases

Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis.